TICKERNERD
Menu
TXMDTXMDHealthcare · Drug Manufacturers - Specialty & Generic

TXMD Stock Forecast: TherapeuticsMD, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.08
+0.97% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile.

Market cap
$23.8M
Ticker Nerd rank
79 / 100
Median analyst target
—
Analysts covering
9
Revenue$724K+84.2% y/y
Operating income−$723K
Net income$95K
Free cash flow$944K
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.5%
1M
+1.0%
YTD
+27.6%
1Y
+89.1%
From 52W high
−24.9%
From 52W low
+100.0%
$1.04
$2.77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TXMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TherapeuticsMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Issuance
84
Accruals
79
Momentum
78
Volatility
73
Value
60
Quality
60
Growth
44
Revisions
25

Size (88): Smaller than most of the companies we track.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TXMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TXMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$1.50$2.00$2.50$3.00Oct 25Jan 26Apr 26Jul 26TXMD

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
17 Aug 2023Cantor FitzgeraldReiteratesNeutral$5.00
17 Aug 2023Cantor FitzgeraldReiteratesNeutral—
11 Jan 2023Cantor FitzgeraldReinstatesNeutral$5.00
13 July 2022Cantor FitzgeraldReiteratesNeutral—
7 June 2022HC Wainwright & Co.DowngradeNeutral—
6 May 2022Cantor FitzgeraldDowngradeNeutral$5.00 → $1.00
11 Mar 2022HC Wainwright & Co.MaintainsBuy$3.00 → $2.50
12 Nov 2021HC Wainwright & Co.MaintainsBuy$4.00 → $3.00
7 Aug 2020JefferiesDowngradeUnderperform$1.25 → $1.20
19 May 2020JP MorganDowngradeNeutral—
7 May 2020H.C. WainwrightReiteratesBuy—
7 May 2020HC Wainwright & Co.ReiteratesBuy$6.00 → $5.00
16 Apr 2020StifelMaintainsBuy$14 → $15
21 Feb 2020H.C. WainwrightMaintainsBuy—
21 Feb 2020HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
14 Aug 2018Cantor FitzgeraldMaintainsOverweight$26 → $27
15 June 2018JP MorganInitiatesOverweight—
8 Sept 2017Morgan StanleyInitiatesEqual-Weight—
21 July 2017Deutsche BankInitiatesBuy—
11 July 2017OppenheimerUpgradeOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TXMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, TherapeuticsMD, Inc. returned +89.1% against +19.6% for the S&P 500, dividends included.

TXMD vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26TXMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TXMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

TherapeuticsMD, Inc. (TXMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
207.0×

Cheaper than 3% of US stocks

Price / sales
7.3×

Cheaper than 18% of US stocks

Price / book
0.9×

Cheaper than 77% of US stocks

EV / EBITDA
−14.8×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
−8.7%

Higher than 17% of US stocks

Earnings growth (YoY)
−71.9%

Higher than 6% of US stocks

Gross margin
—
Operating margin
−32.2%

Higher than 19% of US stocks

Net margin
−6.6%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−1.1%

Higher than 43% of US stocks

Return on assets
−2.9%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TherapeuticsMD, Inc. (TXMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TherapeuticsMD, Inc. has a market value of $23.8M and an enterprise value of $20.2M.

  • Revenue in the twelve months to 31 Mar 2026: $3.4M. The latest quarter shrank 8.7% year on year.

  • Net income over the same four quarters: $179K, a 5.3% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: $2.7M.

  • Shares outstanding: 11.6M.

  • Trailing P/E: 207.0×; forward P/E: 5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • TherapeuticsMD, Inc. employs 1 people — $3.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

TXMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TXMDTherapeuticsMD, Inc.$23.8M
79
BTAIBioXcel Therapeutics, Inc.$24.8M
31
AYTUAytu Biopharma, Inc.$25.4M
62
BFRIBiofrontera, Inc.$22.0M
66
UPCUniverse Pharmaceuticals, Inc.$26.6M
30
OPTHOptimi Health Corp.$27.4M
15
RMTIRockwell Medical, Inc.$32.0M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TherapeuticsMD, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TXMD news & analysis

TherapeuticsMD Announces Second Quarter 2026 Financial Results

Business Wire · 11 Aug 2026negative

TherapeuticsMD reported financial results for the three months ended June 30, 2026, with net income from continuing operations of $164 thousand, compared to $545 thousand in the second quarter of 2025. The report also covered license revenues from continuing operations.

Why it matters — TXMD watchers would care because the company's reported quarterly net income from continuing operations declined compared to the prior-year quarter, indicating a shift in its royalty-focused earnings.

FAQ

Frequently asked questions about TXMD stock

Is TXMD stock a buy right now?

Of the 9 analysts covering TherapeuticsMD, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TherapeuticsMD, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TXMD?

As at 22 Aug 2026, TherapeuticsMD, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

What is the TXMD stock forecast for 2030?

No analyst covering TherapeuticsMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXMD are extrapolating price history, which says nothing about the business.

How has TXMD stock performed over the past year?

TherapeuticsMD, Inc. returned +89.1% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TherapeuticsMD, Inc. do?

TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally.

What is the latest news on TXMD?

The most recent item we track (Business Wire, 11 Aug 2026): "TherapeuticsMD Announces Second Quarter 2026 Financial Results". TherapeuticsMD reported financial results for the three months ended June 30, 2026, with net income from continuing operations of $164 thousand, compared to $545 thousand in the second quarter of 2025. The report also covered license revenues from continuing operations.

Company

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally. The company’s primary role is to develop and license differentiated therapies that address conditions associated with menopause, contraception, and related gynecologic needs. Through licensing agreements, TherapeuticsMD grants commercial rights to partners such as Mayne Pharma for products including hormone therapy and contraceptive offerings, while retaining economic interests via royalties. Its portfolio is complemented by vitamin and prenatal brands historically developed through its VitaMed business, aimed at obstetric and gynecologic practices. By concentrating on proprietary formulations and lifecycle management rather than large-scale sales infrastructure, TherapeuticsMD, Inc. positions itself as an asset-light participant in the pharmaceutical value chain, contributing specialized products to the broader women’s healthcare market.

1 employees · United States · https://www.therapeuticsmd.com